Key facts
- Novartis agreed to acquire Myricx Bio.
- Myricx Bio is a London-based biotech firm.
- The acquisition is valued at up to $1.5 billion.
- The deal aims to bolster Novartis' oncology pipeline.
- Myricx Bio possesses next-generation antibody-drug conjugate technology.
- The technology is for cancer treatment.
Swiss pharmaceutical giant Novartis has announced its agreement to acquire London-based biotech firm Myricx Bio. The deal has a potential value of up to $1.5 billion. This acquisition is designed to strengthen Novartis' existing oncology pipeline. Myricx Bio brings to the table its next-generation antibody-drug conjugate (ADC) technology, which is being developed for the treatment of cancer. The integration of Myricx's technology is anticipated to accelerate the development of new and innovative cancer therapies within Novartis' research and development efforts.